Sodium–glucose cotransporter 2 (SGLT2) inhibitors, widely used to treat type 2 diabetes, can lower blood pressure, blood glucose, and uric acid and protect the heart and kidney [1, 2]. Here, SLC5A2 is linked to type 2 diabetes mellitus.